New study reveals Oxford University's coronavirus vaccine produces strong immune response

Coronavirus vaccine Britain inks deals with Pfizer BioNTech Valneva

A flurry of research, newly released by multiple manufacturers of COVID-19 vaccine candidates, provides reassuring glimmers of hope that scientists are on track to develop an effective and safe vaccine at record speed.

The scientists of Oxford had targeted a million doses of the vaccine by the end of September.

"We do welcome the study and congratulate our colleagues at the Oxford University's General Institute and the Oxford Vaccine Group", said WHO's Health Emergencies Program Executive Director, Michael Ryan. "There is still much work to be done before we can confirm if our vaccine will help manage the COVID-19 pandemic, but these early results hold promise", said Professor Sarah Gilbert, co-author of the study.

People also expressed their happiness by bombarding the platform with memes and jokes, as always.

This vaccine prototype is considered to be the most advanced one among all the samples now in development.

"This means that when the adenovirus enters vaccinated people's cells it also delivers the spike protein genetic code".

Professoer Hill said that neutralising antibodies are produced - molecules which are key to blocking infection.

As per the results, the vaccine boosted T cell and antibody immunity. These larger studies are conducted in broader populations in current disease outbreak sites, in this case South Africa, Brazil and the UK.

Oxford and AstraZeneca are collaborating with clinical partners around the world as part of a global clinical program to trial the Oxford vaccine.

We also need to determine the best way to administer the vaccine.

Kate Bingham, Chair of the UK's Vaccine Taskforce said: "The UK is fortunate to have such outstanding academic innovators working alongside the highly experienced global team at AstraZeneca".

The process is far quicker than making traditional vaccines from a weakened or inactivated form of the virus, which usually takes around five years.

In the study of 60 healthy adults, which was not peer-reviewed, the vaccine induced virus-neutralising antibodies in those given two doses, a result that was in line with a previous early-stage USA trial.

In a statement, CEO of Serum Institute of India said, "The trials have shown promising results and we are extremely happy about it".

Serum Insititute has applied for regulatory approvals to start human trials of the vaccine in India starting August 2020. "Binding antibody response peaked at 656.5 & 571 ELISA units for high & low vaccine dose, respectively", Lancet had tweeted. The side effects caused were monitored, and they will alter the doses in the third phase based on the results of the second phase clinical trials.